CONTACT US
Back to Resources
Back to Resources

Why Precision Oncology Access is Determined Upstream

precision-oncology-access

In precision oncology, the gap between a breakthrough therapy and the patient who needs it is rarely scientific – it's operational. The 2026 OncoGenius® Biomarker Report draws in survey data from 100 U.S. cancer centers and community practices to reveal how provider operations, biomarker testing workflows, and payer policies are shaping access to targeted therapies.

With more than 120 biomarker-defined cancer therapies now in clinical use, the science has never been stronger, but inconsistent testing protocols and fragmented EHR workflows mean that eligible patients are still missing out on treatments. Download the report to understand where the system is falling short and what manufacturers can do to close the gap before treatment decisions are ever made.

Download Report
oncology-access-determined-upstream

What you'll learn:

  • The true cost of testing delays: How gaps in biomarker testing turnaround time affect when patients start treatment and whether they receive the therapy best suited to their molecular profile
  • How payer policies are shaping access upstream: Where prior authorization, coverage inconsistencies, and denial patterns are creating barriers long before a prescription is written
  • What manufacturers can do to drive change: Practical strategies for engaging earlier in the testing pathway to improve patient identification, standardize ordering, and turn regulatory approval into real-world access

Download the report to learn how operational inefficiencies shape when patients receive targeted therapies:

Why Precision Oncology Access is Determined Upstream